Longeveron
LGVN | NASDAQ
$2.14
-$0.35 (-14.06%)
At close: Nov 16, 2026, 4:00 PM ET
$2.14
$0.00 (0.00%)
After-hours:
Nov 16, 2026, 7:30 PM ET
-14.06%
(1D)No price chart data available for 1D timeframe.
Rating
51.8
Fundamentals Average
Market Sentiment Neutral
Moat None
Sector Rank #244/1021 (Top 24%)
Key Statistics
Market Data
Market Cap $6.87M
1D Range
2.14 2.44
52W Range
1.39 11.60
Valuation (TTM)
PE -0.26
PB 1.46
EV/EBITDA -0.00
Valuation (NTM)
Forward PE N/A
Forward PEG 0.01
Price Target $10.00
Cash Flow
FCF Yield -265.4%
SBC Adj. FCF Yield -289.4%
SBC Impact -9.0%
Margins
Gross Margin 66.4%
Operating Margin -2020.8%
FCF Margin -1565.6%
Growth (CAGR)
Revenue 3Y | 5Y 17.1% |
-12.5%
Dil EPS 3Y | 5Y 97.8% |
45.3%
FCF 3Y | 5Y -8.3% |
-5.2%
Returns
ROA -186.3%
ROE -243.3%
ROIC -399.0%
Financial Health
Net Cash
$7.25M
Current Ratio 1.25
Interest Coverage 0.00
Dividends
Div Yield N/A
Payout Ratio N/A
FCF Payout Ratio N/A
Loading financial charts...
Profile
Longeveron Inc. is a biotechnology company currently in the clinical development stage, dedicated to pioneering cell-based therapies. These treatments are designed to address both age-related conditio...
Sector Healthcare
Industry Biotechnology
Employees 38
IPO Date Feb 12, 2021
Website www.longeveron.com
Fiscal Year January - December
Latest News
No news articles available yet.
Earnings
Latest Earnings
Nov 12, 2026
EPS
-$1.91
Miss -12.35%
YoY:
-389.74% REV
$115K
Miss -85.62%
YoY:
-16.06%Next Earnings
Mar 16, 2027
EPS Est
Pro
Rev Est
Pro
Analyst Summary
# of Analysts
2
Consensus
Hold
Price Target
$10.00
Upside
+367.29%
Buy (1)
Hold (1)
Sell (0)
Add to Watchlist
Select watchlists to add or remove LGVN